Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors
{{output}}
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are approved in the U.S. to be given in combination or as single agents to treat patients with BRAF V600E/K-positive solid and histiocytic neoplasms. During postmarketing safety surveillance, we identified case... ...
